Equities Analysts Offer Predictions for Agenus Q1 Earnings

Agenus Inc. (NASDAQ:AGEN) – Equities research analysts at William Blair issued their Q1 2026 EPS estimates for Agenus in a research report issued on Tuesday, March 11th. William Blair analyst M. Phipps expects that the biotechnology company will post earnings per share of ($0.65) for the quarter. The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share. William Blair also issued estimates for Agenus’ Q2 2026 earnings at ($0.64) EPS, Q3 2026 earnings at ($0.64) EPS and Q4 2026 earnings at ($0.64) EPS.

A number of other brokerages have also issued reports on AGEN. Robert W. Baird decreased their price target on Agenus from $6.00 to $3.00 and set a “neutral” rating on the stock in a research note on Wednesday. HC Wainwright restated a “neutral” rating on shares of Agenus in a report on Wednesday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, Agenus currently has a consensus rating of “Hold” and a consensus target price of $8.75.

Agenus Stock Performance

Shares of NASDAQ AGEN opened at $1.68 on Thursday. Agenus has a 1 year low of $1.67 and a 1 year high of $19.69. The firm’s 50 day moving average price is $3.23 and its 200 day moving average price is $3.84. The firm has a market cap of $39.29 million, a P/E ratio of -0.15 and a beta of 1.23.

Agenus (NASDAQ:AGEN) last announced its earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.36) by $0.32. The business had revenue of $26.84 million for the quarter, compared to analyst estimates of $30.09 million.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. FMR LLC boosted its holdings in Agenus by 47.1% in the third quarter. FMR LLC now owns 85,301 shares of the biotechnology company’s stock worth $467,000 after purchasing an additional 27,309 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of Agenus by 2,271.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 39,533 shares of the biotechnology company’s stock valued at $217,000 after buying an additional 37,866 shares during the period. Walleye Capital LLC bought a new stake in shares of Agenus during the 3rd quarter valued at about $1,003,000. HighTower Advisors LLC raised its stake in Agenus by 46.1% during the third quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 7,530 shares during the period. Finally, Point72 DIFC Ltd lifted its holdings in Agenus by 380.0% in the third quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 11,542 shares during the last quarter. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.